Format

Send to

Choose Destination
Neurosci Biobehav Rev. 2016 Mar;62:35-47. doi: 10.1016/j.neubiorev.2015.12.014. Epub 2015 Dec 31.

GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges.

Author information

1
Institute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, United States; Research Service, Olin E. Teague Veterans' Medical Center, Central Texas Veterans Health Care System, Temple, TX, United States; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX, United States. Electronic address: shetty@medicine.tamhsc.edu.
2
Institute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, United States; Research Service, Olin E. Teague Veterans' Medical Center, Central Texas Veterans Health Care System, Temple, TX, United States; Department of Molecular and Cellular Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX, United States.

Abstract

Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.

KEYWORDS:

Epilepsy; GABA-ergic interneurons; Lateral ganglionic eminence; Medial ganglionic eminence; Neural cell grafts; Pain; Schizophrenia; Stem cell therapy; Temporal lobe epilepsy

PMID:
26748379
PMCID:
PMC4869704
[Available on 2017-03-01]
DOI:
10.1016/j.neubiorev.2015.12.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center